NeOnc Technologies Holdings, Inc. entered into a securities purchase agreement for a registered direct offering of common stock and warrants to institutional investors. The company sold 2,610,715 shares of common stock, pre-funded warrants for 960,715 additional shares, and accompanying warrants for 3,571,430 shares at a combined price of $4.20 per share and warrant. Gross proceeds are approximately $15 million before fees. The closing occurred on September 10, 2026. Proceeds will fund working capital and redeem Series A Convertible Preferred Stock. Warrants have a five-year term with a $4.20 exercise price. CEO and CMO executed 90-day lock-up agreements. NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers.

NeOnc Technologies Holdings announced top-line results from the Phase 2a trial of NEO100-01 in recurrent IDH1 mutant high-grade glioma. The study met its primary endpoint, achieving a progression-free survival at six months (PFS6) of 48.9%, significantly exceeding the 20% benchmark with a p-value of 0.0047. Median overall survival was 26.1 months from recurrence, compared to a historical salvage therapy benchmark of six to nine months. The trial enrolled 24 patients, predominantly those with recurrent Grade IV disease. NeOnc plans to present these results to the FDA and pursue accelerated approval via a randomized Phase 3 trial against lomustine. NeOnc Technologies Holdings is a clinical-stage biopharmaceutical company developing novel intranasal therapies for brain cancer.

NeOnc Technologies Holdings announced positive topline results from the Phase 2a portion of its NEO100-01 study in patients with recurrent IDH1-mutant high-grade glioma. The trial met its primary endpoint, achieving a six-month progression-free survival rate of 48.9% against a pre-specified 20% benchmark (p = 0.0047). Median overall survival was 26.09 months, with an 86.7% survival rate at six months and no major toxicities reported. The company plans to request a Type B meeting with the FDA to align on a registrational path for a Phase 3 study. NeOnc Technologies Holdings is a clinical-stage biopharmaceutical company developing novel therapies for central nervous system cancers.

NeOnc Technologies Holdings, Inc. reported second quarter 2026 financial results and announced that topline data from its fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026. The company incurred a net loss of $14.2 million, or $(0.58) per diluted share, compared to a $5.7 million loss in the prior year period. Research and development expenses increased to $2.6 million from $0.7 million, while general and administrative expenses decreased to $0.9 million. As of June 30, 2026, NeOnc held approximately $2.0 million in cash and had an undrawn $10.0 million line of credit with a related party. The company also secured UAE IND approvals for its NEO100 and NEO212 programs and appointed Nasim Shomali to its Board of Directors. NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system cancers.

NeOnc Technologies Holdings, Inc. announced on July 15, 2026, that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding the chemistry, manufacturing, and controls development program for NEO212, its novel temozolomide-perillyl alcohol conjugate. The company is a biotechnology company focused on developing novel oncology-related therapeutics.